WO2010151020A2 - 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 - Google Patents
불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 Download PDFInfo
- Publication number
- WO2010151020A2 WO2010151020A2 PCT/KR2010/004020 KR2010004020W WO2010151020A2 WO 2010151020 A2 WO2010151020 A2 WO 2010151020A2 KR 2010004020 W KR2010004020 W KR 2010004020W WO 2010151020 A2 WO2010151020 A2 WO 2010151020A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oral
- film
- hydrochloride
- sweetener
- acid
- Prior art date
Links
- 235000019640 taste Nutrition 0.000 title claims abstract description 27
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 45
- 239000003765 sweetening agent Substances 0.000 claims abstract description 45
- 235000019202 steviosides Nutrition 0.000 claims abstract description 44
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 41
- 229940013618 stevioside Drugs 0.000 claims abstract description 38
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 25
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 39
- -1 neotime Chemical compound 0.000 claims description 39
- 239000004376 Sucralose Substances 0.000 claims description 33
- 235000019408 sucralose Nutrition 0.000 claims description 33
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 33
- 239000004480 active ingredient Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 30
- 108010011485 Aspartame Proteins 0.000 claims description 26
- 239000000605 aspartame Substances 0.000 claims description 26
- 235000010357 aspartame Nutrition 0.000 claims description 26
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 26
- 229960003438 aspartame Drugs 0.000 claims description 26
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 17
- 229920003169 water-soluble polymer Polymers 0.000 claims description 17
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 15
- 235000010418 carrageenan Nutrition 0.000 claims description 15
- 239000000679 carrageenan Substances 0.000 claims description 15
- 229920001525 carrageenan Polymers 0.000 claims description 15
- 229940113118 carrageenan Drugs 0.000 claims description 15
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 15
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 14
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 14
- 239000004373 Pullulan Substances 0.000 claims description 14
- 229920001218 Pullulan Polymers 0.000 claims description 14
- 229940041616 menthol Drugs 0.000 claims description 14
- 235000019423 pullulan Nutrition 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 235000015165 citric acid Nutrition 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 229960005343 ondansetron Drugs 0.000 claims description 13
- 235000010987 pectin Nutrition 0.000 claims description 13
- 229920001277 pectin Polymers 0.000 claims description 13
- 239000001814 pectin Substances 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims description 11
- 235000010443 alginic acid Nutrition 0.000 claims description 11
- 229920000615 alginic acid Polymers 0.000 claims description 11
- 239000000783 alginic acid Substances 0.000 claims description 11
- 229960001126 alginic acid Drugs 0.000 claims description 11
- 150000004781 alginic acids Chemical class 0.000 claims description 11
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 11
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 11
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims description 11
- 229960002639 sildenafil citrate Drugs 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 9
- AHOUBRCZNHFOSL-UHFFFAOYSA-N 3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 9
- 239000008273 gelatin Substances 0.000 claims description 9
- 229920000159 gelatin Polymers 0.000 claims description 9
- 235000019322 gelatine Nutrition 0.000 claims description 9
- 235000011852 gelatine desserts Nutrition 0.000 claims description 9
- 235000010445 lecithin Nutrition 0.000 claims description 9
- 239000000787 lecithin Substances 0.000 claims description 9
- 229940067606 lecithin Drugs 0.000 claims description 9
- 229960005127 montelukast Drugs 0.000 claims description 9
- 229920000858 Cyclodextrin Polymers 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 8
- 239000004375 Dextrin Substances 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 8
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 8
- 235000019425 dextrin Nutrition 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 229960003310 sildenafil Drugs 0.000 claims description 8
- 239000006188 syrup Substances 0.000 claims description 8
- 235000020357 syrup Nutrition 0.000 claims description 8
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 239000003995 emulsifying agent Substances 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 229960001951 montelukast sodium Drugs 0.000 claims description 7
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical group [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 claims description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 239000003205 fragrance Substances 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 6
- 229960000835 tadalafil Drugs 0.000 claims description 6
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 229960003530 donepezil Drugs 0.000 claims description 5
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 claims description 4
- MKBLHFILKIKSQM-UHFFFAOYSA-N 9-methyl-3-[(2-methyl-1h-imidazol-3-ium-3-yl)methyl]-2,3-dihydro-1h-carbazol-4-one;chloride Chemical group Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 MKBLHFILKIKSQM-UHFFFAOYSA-N 0.000 claims description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000001116 FEMA 4028 Substances 0.000 claims description 4
- 239000001512 FEMA 4601 Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 claims description 4
- JPRXYLQNJJVCMZ-UHFFFAOYSA-N Rizatriptan benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1.C1=C2C(CC[NH+](C)C)=CNC2=CC=C1CN1C=NC=N1 JPRXYLQNJJVCMZ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- 229960004372 aripiprazole Drugs 0.000 claims description 4
- 229960005274 benzocaine Drugs 0.000 claims description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 4
- 229960004853 betadex Drugs 0.000 claims description 4
- YBCNXCRZPWQOBR-WVHCHWADSA-N butylscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 YBCNXCRZPWQOBR-WVHCHWADSA-N 0.000 claims description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 4
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 claims description 4
- VJECBOKJABCYMF-UHFFFAOYSA-N doxazosin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 VJECBOKJABCYMF-UHFFFAOYSA-N 0.000 claims description 4
- 229960000220 doxazosin mesylate Drugs 0.000 claims description 4
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 claims description 4
- 229960000197 esomeprazole magnesium Drugs 0.000 claims description 4
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960004207 fentanyl citrate Drugs 0.000 claims description 4
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 claims description 4
- 229960002024 galantamine hydrobromide Drugs 0.000 claims description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 4
- 229960000905 indomethacin Drugs 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 229960003088 loratadine Drugs 0.000 claims description 4
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 4
- KWORUUGOSLYAGD-WLHYKHABSA-N magnesium;5-methoxy-2-[(r)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide Chemical compound [Mg+2].C([S@@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C.C([S@@](=O)C=1[N-]C2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C KWORUUGOSLYAGD-WLHYKHABSA-N 0.000 claims description 4
- 235000010449 maltitol Nutrition 0.000 claims description 4
- 239000000845 maltitol Substances 0.000 claims description 4
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 4
- 229940035436 maltitol Drugs 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
- 229960000770 ondansetron hydrochloride Drugs 0.000 claims description 4
- 229960005183 paroxetine hydrochloride Drugs 0.000 claims description 4
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 4
- 235000019203 rebaudioside A Nutrition 0.000 claims description 4
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 4
- 229960001534 risperidone Drugs 0.000 claims description 4
- 229960004789 rizatriptan benzoate Drugs 0.000 claims description 4
- 229950009846 scopolamine butylbromide Drugs 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 229960002920 sorbitol Drugs 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 229960005187 telmisartan Drugs 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960001360 zolmitriptan Drugs 0.000 claims description 4
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims description 4
- KTGRHKOEFSJQNS-BDQAORGHSA-N (1s)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 KTGRHKOEFSJQNS-BDQAORGHSA-N 0.000 claims description 3
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 claims description 3
- HWAXMFYECKQLDX-UHFFFAOYSA-N 5-[[(4-chlorobenzoyl)amino]methyl]thiophene-2-sulfonyl chloride Chemical compound C1=CC(Cl)=CC=C1C(=O)NCC1=CC=C(S(Cl)(=O)=O)S1 HWAXMFYECKQLDX-UHFFFAOYSA-N 0.000 claims description 3
- XWSCOGPKWVNQSV-UHFFFAOYSA-N 5-bromo-2,3-dichloropyridine Chemical compound ClC1=CC(Br)=CN=C1Cl XWSCOGPKWVNQSV-UHFFFAOYSA-N 0.000 claims description 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229920000084 Gum arabic Polymers 0.000 claims description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 239000004368 Modified starch Substances 0.000 claims description 3
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000000205 acacia gum Substances 0.000 claims description 3
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical class CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 235000010419 agar Nutrition 0.000 claims description 3
- 239000007961 artificial flavoring substance Substances 0.000 claims description 3
- 229960003416 bambuterol hydrochloride Drugs 0.000 claims description 3
- 229960005086 escitalopram oxalate Drugs 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 3
- 229960001680 ibuprofen Drugs 0.000 claims description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 3
- 229960000991 ketoprofen Drugs 0.000 claims description 3
- 229960003174 lansoprazole Drugs 0.000 claims description 3
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 3
- 235000019426 modified starch Nutrition 0.000 claims description 3
- 229960000381 omeprazole Drugs 0.000 claims description 3
- 229960003617 oxycodone hydrochloride Drugs 0.000 claims description 3
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 3
- 229960001802 phenylephrine Drugs 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 229950008882 polysorbate Drugs 0.000 claims description 3
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 3
- 229960000620 ranitidine Drugs 0.000 claims description 3
- 229960002381 vardenafil Drugs 0.000 claims description 3
- 229960005111 zolpidem tartrate Drugs 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 2
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 claims description 2
- CAVQBDOACNULDN-NRCOEFLKSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 CAVQBDOACNULDN-NRCOEFLKSA-N 0.000 claims description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 claims description 2
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 claims description 2
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 claims description 2
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 229920002148 Gellan gum Polymers 0.000 claims description 2
- 108010068370 Glutens Proteins 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 235000019738 Limestone Nutrition 0.000 claims description 2
- 229920000161 Locust bean gum Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 claims description 2
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 2
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 claims description 2
- RXBKMJIPNDOHFR-UHFFFAOYSA-N Phenelzine sulfate Chemical compound OS(O)(=O)=O.NNCCC1=CC=CC=C1 RXBKMJIPNDOHFR-UHFFFAOYSA-N 0.000 claims description 2
- LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 claims description 2
- KXEMQEGRZWUKJS-UHFFFAOYSA-N Raufloridine Natural products COC1=CC=C2C(CCN3CC4C(C)OC=C(C4CC33)C(=O)OC)=C3NC2=C1 KXEMQEGRZWUKJS-UHFFFAOYSA-N 0.000 claims description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical group OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 102000007544 Whey Proteins Human genes 0.000 claims description 2
- 229920002494 Zein Polymers 0.000 claims description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000571 acetazolamide Drugs 0.000 claims description 2
- 239000001361 adipic acid Substances 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- LFVVNPBBFUSSHL-UHFFFAOYSA-N alexidine Chemical compound CCCCC(CC)CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CC)CCCC LFVVNPBBFUSSHL-UHFFFAOYSA-N 0.000 claims description 2
- 229950010221 alexidine Drugs 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 230000000954 anitussive effect Effects 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- 229940125683 antiemetic agent Drugs 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003907 antipyretic analgesic agent Substances 0.000 claims description 2
- 229940124584 antitussives Drugs 0.000 claims description 2
- 229960004046 apomorphine Drugs 0.000 claims description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 229940049706 benzodiazepine Drugs 0.000 claims description 2
- 150000001557 benzodiazepines Chemical class 0.000 claims description 2
- 229960003789 benzonatate Drugs 0.000 claims description 2
- MAFMQEKGGFWBAB-UHFFFAOYSA-N benzonatate Chemical compound CCCCNC1=CC=C(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C=C1 MAFMQEKGGFWBAB-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 230000003925 brain function Effects 0.000 claims description 2
- 229960003108 brompheniramine maleate Drugs 0.000 claims description 2
- SRGKFVAASLQVBO-BTJKTKAUSA-N brompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 SRGKFVAASLQVBO-BTJKTKAUSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 229960001948 caffeine Drugs 0.000 claims description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- OFAIGZWCDGNZGT-UHFFFAOYSA-N caramiphen Chemical compound C=1C=CC=CC=1C1(C(=O)OCCN(CC)CC)CCCC1 OFAIGZWCDGNZGT-UHFFFAOYSA-N 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000456 carbinoxamine maleate Drugs 0.000 claims description 2
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 239000005018 casein Substances 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims description 2
- 229960001076 chlorpromazine Drugs 0.000 claims description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 2
- RBNWAMSGVWEHFP-UHFFFAOYSA-N cis-p-Menthan-1,8-diol Natural products CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 claims description 2
- 229960002689 clemastine fumarate Drugs 0.000 claims description 2
- 229960004170 clozapine Drugs 0.000 claims description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004126 codeine Drugs 0.000 claims description 2
- 229940124579 cold medicine Drugs 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002069 diamorphine Drugs 0.000 claims description 2
- 229960003529 diazepam Drugs 0.000 claims description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 2
- 229960000616 diflunisal Drugs 0.000 claims description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims description 2
- 210000002249 digestive system Anatomy 0.000 claims description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000520 diphenhydramine Drugs 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 2
- 229960001583 diphenhydramine citrate Drugs 0.000 claims description 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims description 2
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims description 2
- 229960001859 domiphen bromide Drugs 0.000 claims description 2
- 229960005008 doxylamine succinate Drugs 0.000 claims description 2
- 239000003623 enhancer Substances 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 239000003172 expectorant agent Substances 0.000 claims description 2
- 230000003419 expectorant effect Effects 0.000 claims description 2
- 229940066493 expectorants Drugs 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 2
- 235000010492 gellan gum Nutrition 0.000 claims description 2
- 239000000216 gellan gum Substances 0.000 claims description 2
- 235000021312 gluten Nutrition 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 239000001087 glyceryl triacetate Substances 0.000 claims description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 229960003878 haloperidol Drugs 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 2
- 229960000240 hydrocodone Drugs 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 229960004801 imipramine Drugs 0.000 claims description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 229960004903 invert sugar Drugs 0.000 claims description 2
- 229910052741 iridium Inorganic materials 0.000 claims description 2
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims description 2
- 229960004502 levodopa Drugs 0.000 claims description 2
- 229940069445 licorice extract Drugs 0.000 claims description 2
- 239000006028 limestone Substances 0.000 claims description 2
- 235000010420 locust bean gum Nutrition 0.000 claims description 2
- 239000000711 locust bean gum Substances 0.000 claims description 2
- 229960001571 loperamide Drugs 0.000 claims description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 2
- 230000003340 mental effect Effects 0.000 claims description 2
- 229960005181 morphine Drugs 0.000 claims description 2
- 239000002324 mouth wash Substances 0.000 claims description 2
- 229940035363 muscle relaxants Drugs 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 2
- 229960004127 naloxone Drugs 0.000 claims description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 2
- 229960003086 naltrexone Drugs 0.000 claims description 2
- 229960002009 naproxen Drugs 0.000 claims description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 229960002715 nicotine Drugs 0.000 claims description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 229960005118 oxymorphone Drugs 0.000 claims description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229960005489 paracetamol Drugs 0.000 claims description 2
- 229960005152 pentetrazol Drugs 0.000 claims description 2
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 2
- 229960003893 phenacetin Drugs 0.000 claims description 2
- 229960002695 phenobarbital Drugs 0.000 claims description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002895 phenylbutazone Drugs 0.000 claims description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims description 2
- 229960000395 phenylpropanolamine Drugs 0.000 claims description 2
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims description 2
- VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 229960002393 primidone Drugs 0.000 claims description 2
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims description 2
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 2
- 229960003908 pseudoephedrine Drugs 0.000 claims description 2
- 229960004159 pseudoephedrine sulfate Drugs 0.000 claims description 2
- 229940070891 pyridium Drugs 0.000 claims description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 2
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 claims description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 claims description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 2
- 229960001860 salicylate Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000000698 schizophrenic effect Effects 0.000 claims description 2
- 150000004760 silicates Chemical class 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229940083542 sodium Drugs 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 229940100515 sorbitan Drugs 0.000 claims description 2
- 229940071440 soy protein isolate Drugs 0.000 claims description 2
- 229960002573 sultiame Drugs 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 229950010257 terpin Drugs 0.000 claims description 2
- RBNWAMSGVWEHFP-WAAGHKOSSA-N terpin Chemical compound CC(C)(O)[C@H]1CC[C@@](C)(O)CC1 RBNWAMSGVWEHFP-WAAGHKOSSA-N 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 2
- 229960002622 triacetin Drugs 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 229960003500 triclosan Drugs 0.000 claims description 2
- 229960001593 triprolidine hydrochloride Drugs 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 235000021119 whey protein Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 229940093612 zein Drugs 0.000 claims description 2
- 239000005019 zein Substances 0.000 claims description 2
- 150000003752 zinc compounds Chemical class 0.000 claims description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims 1
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229940046413 calcium iodide Drugs 0.000 claims 1
- 229910001640 calcium iodide Inorganic materials 0.000 claims 1
- 238000000354 decomposition reaction Methods 0.000 claims 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 claims 1
- 229960001882 dexchlorpheniramine Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- LPRLDRXGWKXRMQ-UHFFFAOYSA-N diphenylpyraline hydrochloride Chemical compound [Cl-].C1C[NH+](C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 LPRLDRXGWKXRMQ-UHFFFAOYSA-N 0.000 claims 1
- 229960002392 diphenylpyraline hydrochloride Drugs 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 229940091348 latex Drugs 0.000 claims 1
- ITVGXXMINPYUHD-CUVHLRMHSA-N neohesperidin dihydrochalcone Chemical compound C1=C(O)C(OC)=CC=C1CCC(=O)C(C(=C1)O)=C(O)C=C1O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ITVGXXMINPYUHD-CUVHLRMHSA-N 0.000 claims 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229960002244 promethazine hydrochloride Drugs 0.000 claims 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 claims 1
- 235000019204 saccharin Nutrition 0.000 claims 1
- 229940081974 saccharin Drugs 0.000 claims 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 21
- 210000000214 mouth Anatomy 0.000 abstract description 20
- 206010013911 Dysgeusia Diseases 0.000 abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000010408 film Substances 0.000 description 94
- 230000000052 comparative effect Effects 0.000 description 33
- 238000012360 testing method Methods 0.000 description 29
- 230000001953 sensory effect Effects 0.000 description 21
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 18
- 235000010358 acesulfame potassium Nutrition 0.000 description 18
- 229960004998 acesulfame potassium Drugs 0.000 description 18
- 239000000619 acesulfame-K Substances 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 13
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 13
- 235000019477 peppermint oil Nutrition 0.000 description 13
- 239000003826 tablet Substances 0.000 description 12
- 241001310492 Pectis angustifolia Species 0.000 description 11
- 239000001341 hydroxy propyl starch Substances 0.000 description 11
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 11
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 11
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 11
- 229940068968 polysorbate 80 Drugs 0.000 description 11
- 229920000053 polysorbate 80 Polymers 0.000 description 11
- 239000000049 pigment Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 230000000873 masking effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 244000228451 Stevia rebaudiana Species 0.000 description 7
- LWZFANDGMFTDAV-WYDSMHRWSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-WYDSMHRWSA-N 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000004907 flux Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 4
- 229960004294 lercanidipine Drugs 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 210000002200 mouth mucosa Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000032683 aging Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229940094720 viagra Drugs 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- NYVVVBWEVRSKIU-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;n,n-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide Chemical compound OC(=O)C(O)C(O)C(O)=O.N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 NYVVVBWEVRSKIU-UHFFFAOYSA-N 0.000 description 2
- FBCDRHDULQYRTB-UHFFFAOYSA-N 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one;trihydrate;hydrochloride Chemical compound O.O.O.Cl.CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 FBCDRHDULQYRTB-UHFFFAOYSA-N 0.000 description 2
- YYSCJLLOWOUSHH-UHFFFAOYSA-N 4,4'-disulfanyldibutanoic acid Chemical compound OC(=O)CCCSSCCCC(O)=O YYSCJLLOWOUSHH-UHFFFAOYSA-N 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 230000003749 cleanliness Effects 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 229940124447 delivery agent Drugs 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229960004136 rivastigmine Drugs 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 239000001296 salvia officinalis l. Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 229960003553 tolterodine tartrate Drugs 0.000 description 2
- 229960001540 vardenafil hydrochloride Drugs 0.000 description 2
- 229940072018 zofran Drugs 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- RKETZVBQTUSNLM-UHFFFAOYSA-N 6-(3-bromophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole Chemical compound BrC1=CC=CC(C2N=C3SCCN3C2)=C1 RKETZVBQTUSNLM-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- ZOFIRNHZPMLUSA-UHFFFAOYSA-N Cl.C1(=CC=CC=C1)C1=C(NCC1)C1=CC=CC=C1 Chemical compound Cl.C1(=CC=CC=C1)C1=C(NCC1)C1=CC=CC=C1 ZOFIRNHZPMLUSA-UHFFFAOYSA-N 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 244000033273 Dahlia variabilis Species 0.000 description 1
- RRJFVPUCXDGFJB-UHFFFAOYSA-N Fexofenadine hydrochloride Chemical compound Cl.C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RRJFVPUCXDGFJB-UHFFFAOYSA-N 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000019596 Masking bitterness Nutrition 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- PARMADWNFXEEFC-UHFFFAOYSA-N bamethan sulfate Chemical class [O-]S([O-])(=O)=O.CCCC[NH2+]CC(O)C1=CC=C(O)C=C1.CCCC[NH2+]CC(O)C1=CC=C(O)C=C1 PARMADWNFXEEFC-UHFFFAOYSA-N 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 229940119201 cedar leaf oil Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- DMLFJMQTNDSRFU-UHFFFAOYSA-N chlordiazepoxide hydrochloride Chemical compound Cl.O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 DMLFJMQTNDSRFU-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960005372 dexchlorpheniramine maleate Drugs 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001578 eszopiclone Drugs 0.000 description 1
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960000354 fexofenadine hydrochloride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 239000001627 myristica fragrans houtt. fruit oil Substances 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- MUZQPDBAOYKNLO-RKXJKUSZSA-N oxycodone hydrochloride Chemical compound [H+].[Cl-].O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C MUZQPDBAOYKNLO-RKXJKUSZSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 1
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 229930188195 rebaudioside Natural products 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000021012 strawberries Nutrition 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000001040 synthetic pigment Substances 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000001789 thuja occidentalis l. leaf oil Substances 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a film for oral use effectively concealing an unpleasant taste, more specifically, stevioside-based sweeteners and high sweeteners are contained in a ratio (w / w) of 1: 3-3: 1, drug It effectively masks the unpleasant taste of, and relates to the oral film for oral use, which enhances the patient's dose compliance, that is, the after-improving effect that can be dissolved quickly in the oral cavity without water.
- the disintegrating film easily disintegrates or dissolves in the oral cavity, it can be taken without water, so it is very useful for children with disabilities, patients lying in bed, and busy modern people, as well as elderly people who have difficulty taking tablets or capsules. to be. While it is possible to prescribe liquid solutions in place of tablets or capsules for the elderly and children, liquid formulations have the disadvantage of poor stability and inaccurate dosage.
- the liver can also be avoided, so the fast-release film can be applied to drugs that are highly metabolized among the drugs absorbed from the digestive tract.
- US 2008/0044454 discloses a uniform film by coating an active material using various coating techniques and injecting it into a film former. This also makes the coating process cumbersome.
- the present inventors have used aspartame, acesulfame potassium, sucralose and neotime in combination with stevioside and its derivatives to mask bitter and unpleasant taste without significant change in the manufacturing method.
- aspartame, acesulfame potassium, sucralose and neotime in combination with stevioside and its derivatives to mask bitter and unpleasant taste without significant change in the manufacturing method.
- the present inventors solved the problems of the prior art, and as a result of research to develop the most preferred form of the active ingredient-containing oral film, as a result of the high sweetness of sweeteners, especially high steviosides and derivatives thereof known
- sweeteners especially high steviosides and derivatives thereof known
- co-administration with a high sweetness sweetener it was found that the unpleasant taste can be effectively shielded without a separate coating process, and the present invention has been completed.
- an object of the present invention to provide an oral fast-acting film containing a therapeutically effective amount of a medically active ingredient, steviosides and stevioside derivatives, and at least one high sweetener, film former and one or more pharmaceutically acceptable additives. It is.
- Another object of the present invention is to provide an oral cavity film that effectively masks the unpleasant taste of a therapeutically effective amount of a medically active ingredient and dissolves quickly in the oral cavity.
- the present invention has been made in order to achieve the above object, at least one water-soluble polymer, at least one medical active ingredient, stevioside-based sweetener as a tail enhancer, and at least one high sweetener as a taste blocker (first sweetener) It provides an oral rapid use film comprising a.
- Oral quick-release film of the present invention is not only excellent in the unpleasant taste blocking effect, but also can be easily produced by a low cost and simplified recipe, oral cleansers, bad breath removers, nutritional supplement delivery agents and oral and gastrointestinal tract for oral cleanliness It can be usefully used as a snow-soluble agent for the absorption of the drug in.
- Figure 1 shows the results of comparative dissolution experiments of oral fast-acting film prepared according to Example 9 at pH 1.2 and a control drug (Georgine Zidis tablets, GlaxoSmithKline, 8 mg).
- Figure 2 shows the blood profile measured pharmacokinetics using ondansetron film formulation (8mg) and Zofran Zidis tablet (8mg).
- Figure 3 shows the blood concentration comparison profile using the sildenafil citrate film preparation (25mg) and Viagra tablet (25mg).
- FIG 4 shows the blood concentration profile in beagle dogs using montelukast sodium film preparation (5 mg) and singulair chewable tablets (5 mg).
- Figure 5 shows the sweetness profile for each type of high sweetener (first sweetener) according to an embodiment of the present invention. According to Figure 5, the sweetness expression rate is slow in the order of acesulfame potassium (ACK), aspartame (AST), stevioside (STS).
- ACK acesulfame potassium
- AST aspartame
- STS stevioside
- the present invention relates to an oral cavity film composition containing a pharmaceutically active ingredient, effectively masking an unpleasant taste and dissolving rapidly in the oral cavity.
- Preferred fast-acting films according to the present invention comprise a pharmaceutical active agent, stevioside and / or stevioside derivatives, one or more high sweetener (first sweetener), a film former and one or more of the following additional ingredients.
- the additional components consist of pharmaceutically acceptable additives such as saliva stimulants, thickeners, fillers, plasticizers, second sweeteners, acidulants, flavors, emulsifiers, surfactants, binders, preservatives, colorants, coolants.
- pharmaceutically acceptable additives such as saliva stimulants, thickeners, fillers, plasticizers, second sweeteners, acidulants, flavors, emulsifiers, surfactants, binders, preservatives, colorants, coolants.
- a drug having a high taste and a high sweetener (first sweetener) and stevioside and its derivatives for improving the aftertaste are dissolved in water or oil, emulsified and mixed with a water-soluble polymer and other additives to form a rapid film.
- the fast-drying film of this invention contains the 1st sweetener which is a high sweetness sweetener.
- the high sweetness sweetener (first sweetener) is selected from the group consisting of aspartame, acesulfame salt, sucralose, saccharin salt, neotime, cyclate salt, tau martine, Nahan fruit extract, licorice extract It may be one or more high sweetening sweeteners. More preferably, at least one high sweetener sweetener selected from aspartame, sucralose, neotime, acesulfame salts.
- stevioside examples include stevittenite (over 98% stevioside), stevitenrich (100% enzymatically treated stevia) and stevia extract REB-A73% (rebaudioside A 73% or more) produced by Daepyung ) And lebaten 97% (more than 97% Rebaudioside A).
- the enzyme-treated stevia is a product in which glucose is added to the stevia extract by using a sugar transfer enzyme, and is a microporous improvement product which reduces the intrinsic bitter taste of stevioside and enhances solubility.
- 97% of lebaten is the sweetest and most sweet ingredient among the seven sweet components of stevia, and is produced through a separate separation operation in stevia.
- Oral rapid-release film of the present invention contains a water-soluble polymer.
- the water-soluble polymer is pullulan, gelatin, pectin, low viscosity pectin, hydroxypropyl methyl cellulose, low viscosity hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, polyvinyl alcohol, polyacrylic acid, Methyl methacrylate copolymer, carboxyvinyl polymer, polyethylene glycol, alginic acid, low viscosity alginic acid, sodium alginate, carrageenan, modified starch, casein, whey protein isolate, soy protein isolate, zein, levan, elcinane, gluten, acacia At least one water-soluble polymer selected from the group consisting of gums, carrageenan, gum arabic, guar gum, locust bean gum, xanthan gum, gellan gum and agar.
- the water-soluble polymer may be at least one water-soluble polymer selected from the group consisting of pullulan, gelatin, pectin, low viscosity pectin, low viscosity alginic acid, hydroxypropylmethylcellulose and modified starch.
- the water-soluble polymer is 50 to 90% by weight (w / w), preferably 60 to 80% by weight (w / w), more preferably 60 to 70% by weight (w / w) relative to the total weight of the film It may contain.
- the pharmacologically active ingredient used in the rapid-release film of the present invention may be a pharmacologically active ingredient orally administered, but particularly, a drug capable of quickly exhibiting medicinal effects by exhibiting rapid dissolution is preferable.
- Antidiabetic agents such as, for example, glimepiride, pioglitazone, and the like; Agents for treating insomnia such as zolpidem, eszopiclone and the like; Urogenital therapeutics such as tolterodine, tropium and the like; Anti-obesity agents such as sibutramine and the like; Enzymes such as streptokinase and the like; Peptic ulcer solvents such as omeprazole; Antitussive expectorants such as theophylline, glenbuterol and the like; Skin disease treatment agents such as finasteride and the like; Antiemetic agents such as ondansetron; Antidepressants such as fluoxetine and the like; Antihistamines such as fexofen
- the pharmaceutically active ingredient is triclosan, cetyl pyridium chloride, domiphen bromide, quaternary ammonium salt, zinc compound, acid guinarin, fluoride, alexidine, octonidine, EDTA, aspirin, acetaminophen, ibuprofen, ketoprofen, Diflunisal, Phenopropenecalcium, Naproxen, Tolmethinine Sodium, Indomethacin, Benzonatate, Caramiphene, Edsylate, Menthol, Dextromeropane Hydrobromide, Crofedianol Hydrochloride, Diphenhydramine, Pseudoephedrine, phenylephrine, phenylpropanolamine, pseudoephedrine sulfate, brompheniramine maleate, chlorpheniramine maleate, carbinoxamine maleate, clemastine fumarate, dexchlorpheniramine maleate, di
- the oral rapid-release film containing the ondansetron hydrochloride as a medical active ingredient may have biological equivalence.
- the montelukast salt is montelukast sodium
- oral film for oral use containing the montelukast sodium as a medical active ingredient may have bioequivalence.
- the oral rapid-release film containing the sildenafil citrate as a medical active ingredient may have bioequivalence.
- the active ingredient may contain 0.1 to 30% by weight (w / w), preferably 10 to 20% by weight (w / w), based on the total weight of the flux film.
- the filler serves to reduce the slippery properties of the film in the oral cavity and to impart a backbone to the film. It also reduces the sticking properties of the films, and can control the sticking and dissolution rate of the film in the oral cavity and the dissolution rate of the drug.
- the filler may be added to 1 to 15% by weight (w / w) relative to the total weight of the flux film.
- the filler may be one or more components selected from the group consisting of microcrystalline cellulose, cellulose polymers, magnesium carbonate, calcium carbonate, limestone powder, silicates, clays, talc, titanium dioxide and calcium phosphate.
- the plasticizer can be used to adjust the flexibility of the film.
- the plasticizer may be added in an amount of 0.1 to 15 wt% (w / w) based on the total weight of the flux film.
- the plasticizer is at least one selected from the group consisting of sorbitol, maltitol, xylitol, glycerin, polyethylene glycol, propylene glycol, hydrogenated syrup, syrup, glycerin, triacetin, glycerololate, sucrose fatty acid ester, and medium chain fatty acid. It may be a component.
- the fastener film of the present invention may include a second sweetener.
- the second sweetener may be added 0.1 to 10% by weight (w / w) relative to the total weight of the edible film.
- the sweetener is sugar, glucose, maltose, oligosaccharide, dextrin, alpha cyclodextrin, beta cyclodextrin, gamma cyclodextrin, methyl beta cyclodextrin, hydroxypropyl beta cyclodextrin, cluster dextrin , Indigestible dextrin, hydrogenated indigestible dextrin, invert sugar, fructose, lactose, galactose, syrup, sorbitol, maltitol, xylitol, erythritol, hydrogenated syrup, mannitol, and trehalose.
- the oral rapid release film of the present invention may also further comprise an acidulant.
- the acidulant together with the sweetener, controls the taste and may play a role in stimulating the generation of saliva so that the edible film can be dissolved well.
- the acidulant may be added to 0.1 to 10% by weight (w / w) based on the total weight of the rapid film composition.
- the acidulant may be at least one component selected from the group consisting of citric acid, malic acid, fumaric acid, tartaric acid, ascorbic acid, succinic acid, adipic acid and lactic acid.
- the oral rapid release film of the present invention may also contain a fragrance. Since the rapid-release film of the present invention is a product that is dissolved and absorbed in the oral cavity, it is necessary to add an appropriate scent.
- the flavor may be natural flavors, artificial flavors or mixtures thereof.
- Natural flavors may be extracts from the leaves, flowers, fruits and the like of plants, oils of plants and the like.
- Plant oils include spearmint oil, cinnamon oil, peppermint oil, lemon oil, clove oil, bay oil, thyme oil, cedar leaf oil, nutmeg oil and sage ( sage) oil, almond oil, and the like.
- artificial flavors of fruits such as lemons, oranges, grapes, limes, strawberries and artificial synthetic flavors such as vanilla, chocolate, coffee, cocoa, pine needles, ginseng, red ginseng, citrus may be used.
- the amount of fragrance used depends on a number of factors such as the type, type, and desired strength of the fragrance that is commonly used, and may generally comprise 1 to 15 wt% (w / w) relative to the total weight of the generic film.
- Perfume in oil form may be used together with an emulsifier to make it compatible with water-soluble substances.
- the amount of the emulsifier may be adjusted according to the type and amount of the fragrance, and generally, 0.1 to 10% by weight (w / w) may be added to the total weight of the generic film.
- the emulsifier may be at least one component selected from the group consisting of glycerin fatty acid ester, sucrose fatty acid ester, lecithin, enzyme treated lecithin, polysorbate, sorbitan fatty acid ester and propylene glycol.
- the oral film for oral use of the present invention may contain a pigment suitable for the product.
- the pigment may be appropriately adjusted in its content as necessary, and in general, 0.01 to 10% by weight (w / w) may be added to the total weight of the edible film.
- the pigment may be a natural or synthetic pigment.
- the oral rapid release film of the present invention may also further comprise a freshener.
- the coolant may be, for example, but not limited to, WS3, WS23 or Questais-L.
- the freshener may be appropriately adjusted in amount as necessary, and may be generally added in an amount of 0.01 to 5 wt% (w / w) based on the total weight of the soft film.
- the present invention also provides a flux film comprising the oral flux film composition.
- the oral rapid-release film of the present invention will preferably form a thin film that maintains an appropriate range of tensile strength and toughness in a very thin film state.
- the thickness of the rapid-release film of this invention is 20 micrometers-200 micrometers, Preferably it is 40 micrometers-100 micrometers.
- the present invention also provides a method for producing the oral flux film.
- the method for producing a rapid-release film of the present invention is a rapid-release film of the present invention.
- (3) may comprise aging the molded film at a relative humidity of 50 to 70% for 1 to 10 days.
- the method for producing an edible film according to the present invention can be carried out through, for example, the following process.
- 2nd solution manufacturing process The 2nd solution which mixed additives, such as a pigment, a sweetener, an acidulant, and a filler, is prepared.
- 3rd solution manufacturing process The 3rd solution is prepared by mixing an active ingredient, menthol, a fragrance, and a freshener with an emulsifier.
- the 4th solution is prepared by mixing the said 2nd solution and the said 3rd solution.
- e) 5th solution manufacturing process It raises the temperature to 60 degreeC or more, and mixes the said 1st solution and the said 4th solution, and manufactures a 5th solution.
- the fifth solution is filtered and then introduced into a molding machine to form a film.
- the temperature of the molding machine is 50 to 80 °C and manufactured in roll form through a belt drum dryer.
- the molded film contains moisture suitable for slitting or cutting through a aging process of about 1 to 10 days at a relative humidity of 50 to 70%. At this time, the water content is appropriately 8 to 12%.
- the following process may be further performed as a subsequent process of the manufacturing method.
- the aged rolls are slits into small rolls, cut into appropriate sizes and filled into small containers or aluminum wrappers.
- Filled small containers or aluminum bags are repackaged in small boxes or blistered into products.
- the rapid-release film prepared by the method of the present invention is quickly disintegrated and dissolved by saliva in the oral cavity without eating water, it can be easily administered to patients or elderly and children who are difficult to swallow tablets.
- Meloxycam was added as a pharmaceutically active ingredient to prepare a film according to the composition shown in Table 1 below.
- Aspartame and starch oxide were used by Daesang Co., Ltd., Acesulfame potassium was manufactured by Nutrinova, Sucralose was produced by Tate & Lyle, Carrageenan was manufactured by MSC, and Polysorbate was manufactured by Ilshin Wells. The product, pullulan was used by Hayashibara, and peppermint oil and lemon by Borax.
- Example 4 wt% Example 5 wt% Example 6 wt% Example 7 wt% Example 8 wt% Sucralose 2.5 2.5 2.5 2.5 2.5 2.5 Stevioside 3.5 3.5 3.5 3.5 3.5 3.5 Citric acid 0.6 0.6 0.6 0.6 Hydroxypropyl starch 5 5 5 5 5 5 5 lecithin 0.4 0.4 0.4 0.4 0.4 0.4 menthol 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Car
- Low viscosity pectin is CIPIKELCO's GENU pectin DSS
- gelatin is Geltech's 100 Bloom product
- hydroxypropylmethylcellulose is Demasa's demacol HE 5/6 BV
- low viscosity alginic acid is MSC's login
- hydroxypropyl starch Grain Processing Corp. used the product.
- Ondansetron, zolpidem tartrate, tadalafil, lercanidipine and donepies were added as pharmaceutically active ingredients to prepare films according to the compositions shown in Table 6.
- the composition from which steviosides are removed is shown in Table 7.
- Films were prepared according to the compositions described in Tables 6 and 7, and placed in the mouths of six adult men and women, the time at which the film completely disintegrated by the saliva of the oral cavity was measured, and the sensory test was performed. Sensory tests were performed randomly and are described in Table 8 below.
- the pharmacokinetic test was carried out using Zonfran Gidis tablets of GlaxoSmithKline (GSK), a commercially available product containing ondansetron fast-acting film prepared according to Example 9 of the present invention and ondansetron.
- the experiment was conducted in accordance with the Latin Explosion Method on 14 healthy adult men according to the bioequivalence test criteria announced by the Food and Drug Administration.
- Group 1 is Bexcore ondansetron film preparation (8mg),
- Group 2 is Zorfran ® Zydis ODT
- sildenafil free base sildenafil lactate, sildenafil citrate, granistron, and montelukast sodium were added to prepare a film according to the composition of Table 10. Sensory tests were performed randomly and the degree of masking unpleasant aftertaste was excellent.
- Example 16 (% by weight) Example 17 (% by weight) Example 18 (% by weight) Example 19 (% by weight) Example 20 (% by weight) Sucralose 1.7 2 2 1.5 0.5 Neotam One 2 0 Acesulfame Potassium 0.5 0.5 One 0.5 97% lebatten 2 2 2 2 0.5 Citric acid 0.2 0.2 0.2 0.6 0.6 Hydroxypropyl starch 2 2 One 3 2 Span20 0.1 0.5 0.1 0.4 0.4 menthol 0.4 2.3 0.3 3 3 3 Carrageenan 0.1 0.1 0.1 0.1 0.2 Pigment 0.1 0.1 0.1 0.1 Polysorbate 80 0.4 0.5 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 Peppermint Oil 0.8 2.7 0.6 3 3 Pullulan 62.3 77.5 55.1 81.5 78.9 Microcrystalline cellulose 1.4 1.4 0.7 1.5 4 Betacyclodextrin 0.7 Lemon scent 2 2 0.8 1.5 1.5 Sildenafil Flip Base 25 Sildenafil lactate 4.2 Sildenafil Citrate
- the pharmacokinetic test was carried out using Sildenafil citrate quick-release film prepared according to Example 18 of the present invention and Viagra tablets of Pfizer Co., Ltd., a general commercial product containing sildenafil citrate.
- the experiment was conducted in accordance with the Latin Explosion Method on eight healthy adult men according to the bioequivalence test criteria announced by the Food and Drug Administration.
- Group 1 is Bexcore sildenafil film preparation (25mg)
- Group 2 is Viagra ® tablets (25 mg)
- test animals 6 healthy male beagle dogs, each weighing 10.20 to 12.20 kg (10.99 ⁇ 0.87 kg), were used per specimen and were reared in each cage for about 2 weeks before the experiment.
- a control formulation was used Singulair Chew tablets (5 mg, Merck), and the test formulation was used as a fast-acting film containing 5 mg of montelukast per 100 mg as the formulation of Example 20.
- the test animals were divided into two groups of 6 heads and orally administered the control agent and the test agent. In general, oral administration of the drug was carried out by pushing an amount corresponding to 5 mg per beagle dog with water.
- Group 1 is Bexcore montelukast genus film preparation (5mg),
- Group 2 is Singulair chewable tablet (5mg)
- Galantamine hydrobromide, doxazosin mesylate, tolterodine tartrate, paroxetine hydrochloride, and bambuterol hydrochloride were added as pharmaceutically active ingredients to prepare films according to the compositions shown in Table 13. Sensory tests were performed randomly and the degree of masking unpleasant aftertaste was excellent.
- Example 23 (% by weight) Example 24 (% by weight) Example 25 (% by weight) Example 26 (% by weight) Example 27 (% by weight) Sucralose 1.6 1.7 2 1.5 Aspartame 2.5 Acesulfame Potassium 0.6 0.5 0.7 0.5 97% lebatten 2 1.9 2 2 1.5 Citric acid 0.2 0.2 0.2 0.6 0.6 Hydroxypropyl starch 2 2 2 3 2 Span20 0.1 0.5 0.1 0.4 0.4 menthol 0.4 2.3 0.3 3 3 3 Carrageenan 0.1 0.1 0.1 0.1 0.2 Pigment 0.1 0.1 0.1 0.1 Polysorbate 80 0.4 0.5 0.3 0.3 0.3 0.3 0.3 0.3 0.3 Peppermint Oil 0.8 2.7 0.6 3 3 3 Pullulan 78.3 74.1 87.4 63.5 71.9 Microcrystalline cellulose 1.4 1.4 0.7 0.5 3 Lemon scent 2 2 1.5 1.5 1.5 Galantamine hydrobromide 10 Doxazosin mesylate 10 Tolterodine Tartrate 2 Paroxe
- Polcodine, butylscopolamine, fentanyl citrate, oxycodone hydrochloride and buprenol hydrochloride were added as pharmaceutically active ingredients to prepare films according to the compositions in Table 14. Sensory tests were performed randomly and the degree of masking unpleasant aftertaste was excellent.
- Example 28 (% by weight) Example 29 (% by weight) Example 30 (% by weight) Example 31 (% by weight) Example 32 (% by weight) Sucralose 1.7 1.5 2 1.5 Aspartame 1.5 Acesulfame Potassium 0.5 0.6 0.7 0.5 97% lebatten 2 2 2 2 1.5 Citric acid 0.2 0.2 0.2 0.6 0.6 Hydroxypropyl starch 2 2 3.8 3 4 Span20 0.1 0.5 0.1 0.4 0.4 menthol 0.4 2.3 0.3 3 3 3 Carrageenan 0.1 0.1 0.1 0.1 0.2 Pigment 0.1 0.1 0.1 0.1 Polysorbate 80 0.4 0.5 0.3 0.3 0.3 0.3 Peppermint Oil 0.8 2.7 1.6 3 3 3 Pullulan 78.3 74.1 86.4 71.5 74.9 Microcrystalline cellulose One One 0.4 0.5 3.5 Betacyclodextrin 0.4 0.4 0.3 0.5 0.5 Lemon scent 2 2 1.5 One 1.5 Polcodine 10 Butyl Scopolamine 10 Fentanyl citrate 0.2 Bupren
- Hydromol hydrochloride, ecitalopram oxalate, rivastigmine tartarate, esomeprazole magnesium and aripiprazole were added as pharmaceutically active ingredients to prepare a film according to the composition of Table 15. Sensory tests were performed randomly and the degree of masking unpleasant aftertaste was excellent.
- Example 33 (% by weight) Example 34 (% by weight) Example 35 (% by weight) Example 36 (% by weight) Example 37 (% by weight) Sucralose 1.7 1.6 2 1.5 Aspartame 1.5 Acesulfame Potassium 0.5 0.5 0.7 0.5 97% lebatten 2 2 2 2 1.5 Citric acid 0.2 0.2 0.2 0.6 0.6 Hydroxypropyl starch 4 2 3.8 3 4 Span20 0.1 0.5 0.1 0.4 0.4 menthol 0.4 2.3 0.3 3 3 3 Carrageenan 0.1 0.1 0.1 0.1 0.2 Pigment 0.1 0.1 0.1 0.1 Polysorbate 80 0.4 0.5 0.3 0.3 0.3 0.3 0.3 0.3 0.3 Peppermint Oil 0.8 2.7 0.6 3 3 3 Pullulan 79.3 74.1 81.6 71.5 61.9 Microcrystalline cellulose 4.4 1.4 3.7 2.5 2 Lemon scent 2 2 1.5 1.5 1.5 Hydrochloric acid hydrochloride 4 Escitalopram oxalate 10 Rivastigmine tartarate 3 Aripiprazol
- Zolmitriptan, rizatriptan benzoate, telmisartan, risperidone and vardenafil hydrochloride were added as pharmaceutically active ingredients to prepare films according to the compositions shown in Table 16. Sensory tests were performed randomly and the degree of masking unpleasant aftertaste was excellent.
- Benzocaine, loratidine, phenylephrine hydrochloride, diphenhydramine hydrochloride, dextromemethane hydrobromide and cerizine hydrochloride were added as pharmaceutically active ingredients to prepare films according to the compositions in Table 17. Sensory tests were performed randomly and the degree of masking unpleasant aftertaste was excellent.
- Example 43 (% by weight) Example 44 (% by weight) Example 45 (% by weight) Example 46 (% by weight) Example 47 (% by weight) Example 48 (% by weight) Sucralose 1.7 1.6 One 1.5 One One Neotam 0.5 0.5 Acesulfame Potassium 0.5 0.5 0.7 0.5 97% lebatten 2 2 2 2 1.5 1.5 Citric acid 0.2 0.2 0.2 0.6 0.6 Hydroxypropyl starch 5 2 5 3 4 4 Span20 0.1 0.5 0.1 0.4 0.4 0.4 menthol 0.4 1.3 0.3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 Carrageenan 0.1 0.1 0.1 0.2 0.2 Pigment 0.1 0.1 0.1 0.1 Polysorbate 80 0.4 0.5 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 Peppermin
- Oral quick-release film of the present invention is not only excellent in the unpleasant taste blocking effect, but also can be easily produced by a low cost and simplified recipe, oral cleansers, bad breath removers, nutritional supplement delivery agents for oral cleanliness and oral and gastrointestinal tract It can be usefully used as a snow-soluble agent for the absorption of the drug in.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
성 분 | 비교예 1 wt% | 비교예 2 wt% | 비교예3 wt% | 실시예 1 wt% | 실시예2 wt% | 실시예 3 wt% |
아스파탐 | 2.5 | 2.5 | ||||
슈크랄로스 | 2.5 | 2.5 | ||||
아세설팜칼륨 | 2.5 | 2.5 | ||||
스테비오사이드 | 3.5 | |||||
효소처리스테비아 | 3.5 | |||||
레바우디오사이드 | 3.5 | |||||
구연산 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 |
산화전분 | 5 | 5 | 5 | 5 | 5 | 5 |
레시틴 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
멘톨 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
카라기난 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
폴리솔르베이트80 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
페퍼민트오일 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
풀루란 | 66.6 | 66.6 | 66.6 | 63.1 | 63.1 | 63.1 |
미세결정셀룰로스 | 3 | 3 | 3 | 3 | 3 | 3 |
레몬향 | 2 | 2 | 2 | 2 | 2 | 2 |
멜록시캄 | 18 | 18 | 18 | 18 | 18 | 18 |
계 | 100 | 100 | 100 | 100 | 100 | 100 |
감미제 | 구강붕해시간(초) | 초기관능시험결과 | 1분후의 관능시험결과 | |
비교예1 | 아스파탐 | 55 | 1 | 5 |
비교예2 | 슈크랄로스 | 53 | 1 | 4 |
비교예3 | 아세설팜-칼륨 | 54 | 1 | 5 |
실시예1 | 아스파탐+스테비오사이드 | 51 | 1 | 1 |
실시예2 | 슈크랄로스+효소처리스테비오사이드 | 52 | 1 | 1 |
실시예3 | 아세설팜-칼륨+레바우디오사이드-A | 53 | 1 | 1 |
성 분 | 실시예 4wt% | 실시예 5wt% | 실시예 6wt% | 실시예 7wt% | 실시예8wt% |
슈크랄로스 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
스테비오사이드 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 |
구연산 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 |
하이드록시프로필전분 | 5 | 5 | 5 | 5 | 5 |
레시틴 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
멘톨 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
카라기난 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
폴리솔르베이트80 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
페퍼민트오일 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
저점도펙틴 | 63.1 | ||||
젤라틴 | 63.1 | ||||
HPMC | 63.1 | ||||
저점도 알긴산 | 63.1 | ||||
폴리비닐알콜 | 63.1 | ||||
미세결정셀룰로스 | 3 | 3 | 3 | 3 | 3 |
레몬향 | 2 | 2 | 2 | 2 | 2 |
멜록시캄 | 18 | 18 | 18 | 18 | 18 |
계 | 100 | 100 | 100 | 100 | 100 |
성 분 | 비교예 4wt% | 비교예 5wt% | 비교예 6wt% | 비교예 7wt% | 비교예8wt% |
슈크랄로스 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
구연산 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 |
하이드록시프로필전분 | 5 | 5 | 5 | 5 | 5 |
레시틴 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
멘톨 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
카라기난 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
폴리솔르베이트80 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
페퍼민트오일 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
저점도펙틴 | 66.6 | ||||
젤라틴 | 66.6 | ||||
HPMC | 66.6 | ||||
저점도 알긴산 | 66.6 | ||||
폴리비닐알콜 | 66.6 | ||||
미세결정셀룰로스 | 3 | 3 | 3 | 3 | 3 |
레몬향 | 2 | 2 | 2 | 2 | 2 |
멜록시캄 | 18 | 18 | 18 | 18 | 18 |
계 | 100 | 100 | 100 | 100 | 100 |
구분 | 감미제 | 수용성고분자 | 구강붕해시간(초) | 초기관능시험결과 | 1분후의 관능시험결과 |
실시예4 | 슈크랄로스+스테비오사이드 | 펙틴 | 57 | 1 | 1 |
비교예4 | 슈크랄로스 | 펙틴 | 59 | 1 | 4 |
실시예5 | 슈크랄로스+스테비오사이드 | 젤라틴 | 54 | 1 | 1 |
비교예5 | 슈크랄로스 | 젤라틴 | 55 | 1 | 4 |
실시예6 | 슈크랄로스+스테비오사이드 | HPMC | 53 | 1 | 1 |
비교예6 | 슈크랄로스 | HPMC | 54 | 1 | 4 |
실시예7 | 슈크랄로스+스테비오사이드 | 알긴산 | 56 | 1 | 1 |
비교예7 | 슈크랄로스 | 알긴산 | 58 | 1 | 4 |
실시예8 | 슈크랄로스+스테비오사이드 | PVA | 53 | 1 | 1 |
비교예8 | 슈크랄로스 | PVA | 54 | 1 | 4 |
성 분 | 실시예 9wt% | 실시예 10wt% | 실시예 11wt% | 실시예 12wt% | 실시예 13wt% |
슈크랄로스 | 1 | 1.2 | |||
아스파탐 | 4 | 3 | 3 | 1 | 1.2 |
아세설팜칼륨 | 1 | ||||
스테비오사이드 | 4 | 3 | 2 | 1 | 1.2 |
구연산 | 0.2 | 0.2 | 0.2 | 0.6 | 0.6 |
하이드록시프로필전분 | 4 | 4 | 2 | 0.3 | 4 |
레시틴 | 0.1 | 0.5 | 0.1 | 0.4 | 0.4 |
멘톨 | 0.4 | 2.3 | 0.3 | 3 | 3 |
카라기난 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 |
폴리솔르베이트80 | 0.4 | 0.5 | 0.3 | 0.3 | 0.3 |
페퍼민트오일 | 0.8 | 2.7 | 0.6 | 3 | 3 |
풀루란 | 72.5 | 59.4 | 68.2 | 72.1 | 69.4 |
미세결정셀룰로스 | 1.4 | 1.4 | 0.7 | 0.7 | 4 |
레몬향 | 2 | 2 | 1.5 | 1.5 | 1.5 |
온단세트론 | 10.1 | ||||
졸피뎀 타르타레이트 | 20.9 | ||||
타다라필 | 20.0 | ||||
레르카니디핀 | 15 | ||||
도네피질 | 10 | ||||
계 | 100 | 100 | 100 | 100 | 100 |
성 분 | 비교예 9wt% | 비교예 10wt% | 비교예 11wt% | 비교예 12wt% | 비교예 13wt% |
슈크랄로스 | 1 | 1.2 | |||
아스파탐 | 4 | 3 | 3 | 1 | 1.2 |
아세설팜칼륨 | 1 | ||||
스테비오사이드 | 0 | 0 | 0 | 0 | 0 |
구연산 | 0.2 | 0.2 | 0.2 | 0.6 | 0.6 |
하이드록시프로필전분 | 4 | 4 | 2 | 0.3 | 4 |
레시틴 | 0.1 | 0.5 | 0.1 | 0.4 | 0.4 |
멘톨 | 0.4 | 2.3 | 0.3 | 3 | 3 |
카라기난 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 |
폴리솔르베이트80 | 0.4 | 0.5 | 0.3 | 0.3 | 0.3 |
페퍼민트오일 | 0.8 | 2.7 | 0.6 | 3 | 3 |
풀루란 | 76.5 | 62.4 | 70.2 | 73.1 | 70.6 |
미세결정셀룰로스 | 1.4 | 1.4 | 0.7 | 0.7 | 4 |
레몬향 | 2 | 2 | 1.5 | 1.5 | 1.5 |
온단세트론 | 10.1 | ||||
졸피뎀 타르타레이트 | 20.9 | ||||
타다라필 | 20.0 | ||||
레르카니디핀 | 15 | ||||
도네피질 | 10 | ||||
계 | 100 | 100 | 100 | 100 | 100 |
구분 | 감미제 | 구강붕해시간(초) | 초기 관능 시험결과 | 1분후의 관능시험결과 |
실시예9 | 아스파탐+스테비오사이드 | 53 | 1 | 1 |
비교예9 | 아스파탐 | 54 | 1 | 5 |
실시예10 | 아스파탐+스테비오사이드 | 49 | 1 | 1 |
비교예10 | 아스파탐 | 50 | 1 | 5 |
실시예11 | 아스파탐+아세설팜칼륨+스테비오사이드 | 51 | 1 | 1 |
비교예11 | 아스파탐+아세설팜칼륨 | 52 | 1 | 4 |
실시예12 | 슈크랄로스+아스파탐+스테비오사이드 | 53 | 1 | 1 |
비교예12 | 슈크랄로스+아스파탐 | 55 | 1 | 4 |
실시예13 | 슈크랄로스+아스파탐+스테비오사이드 | 52 | 1 | 1 |
비교예13 | 슈크랄로스+아스파탐 | 53 | 1 | 4 |
파라미터 | 그룹 1 | 그룹 2 |
AUC0~24(ng.hr/mL) | 244.78± 91.83 | 259.64 ± 87.10 |
Cmax(ng/mL) | 30.93± 10.71 | 33.16 ± 8.89 |
Tmax(hr) | 1.86± 0.71 | 1.94±0.75 |
성 분 | 실시예 16 (중량%) | 실시예 17 (중량%) | 실시예 18 (중량%) | 실시예 19 (중량%) | 실시예 20 (중량%) |
슈크랄로스 | 1.7 | 2 | 2 | 1.5 | 0.5 |
네오탐 | 1 | 2 | 0 | ||
아세설팜칼륨 | 0.5 | 0.5 | 1 | 0.5 | |
레바텐 97% | 2 | 2 | 2 | 2 | 0.5 |
구연산 | 0.2 | 0.2 | 0.2 | 0.6 | 0.6 |
하이드록시프로필전분 | 2 | 2 | 1 | 3 | 2 |
스판20 | 0.1 | 0.5 | 0.1 | 0.4 | 0.4 |
멘톨 | 0.4 | 2.3 | 0.3 | 3 | 3 |
카라기난 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 |
색소 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
폴리솔르베이트80 | 0.4 | 0.5 | 0.3 | 0.3 | 0.3 |
페퍼민트오일 | 0.8 | 2.7 | 0.6 | 3 | 3 |
풀루란 | 62.3 | 77.5 | 55.1 | 81.5 | 78.9 |
미세결정셀룰로스 | 1.4 | 1.4 | 0.7 | 1.5 | 4 |
베타사이클로덱스트린 | 0.7 | ||||
레몬향 | 2 | 2 | 0.8 | 1.5 | 1.5 |
실데나필 플리베이스 | 25 | ||||
실데나필 락테이트 | 4.2 | ||||
실데나필 시트레이트 | 35 | ||||
염산 그라니세트론 | 1 | ||||
몬테루카스트 나트륨 | 5 | ||||
계 | 100 | 100 | 100 | 100 | 100 |
파라미터 | 그룹 1 | 그룹 2 |
AUC0~24(ng.hr/mL) | 711.87± 89.38 | 728.64 ± 87.10 |
Cmax(ng/mL) | 255.39± 31.17 | 269.24 ± 88.90 |
Tmax(hr) | 0.83± 0.42 | 0.81 ± 0.35 |
파라미터 | 그룹 1 | 그룹 2 |
AUC0~24(ng.hr/mL) | 12398± 3029.7 | 12151.2 ± 1353.3 |
Cmax(ng/mL) | 1010.7± 226.7 | 962.0 ± 73.2 |
Tmax(hr) | 5.3± 3.3 | 4.0± 0.0 |
성분 | 실시예 23 (중량%) | 실시예 24 (중량%) | 실시예 25 (중량%) | 실시예 26 (중량%) | 실시예 27 (중량%) |
슈크랄로스 | 1.6 | 1.7 | 2 | 1.5 | |
아스파탐 | 2.5 | ||||
아세설팜칼륨 | 0.6 | 0.5 | 0.7 | 0.5 | |
레바텐 97% | 2 | 1.9 | 2 | 2 | 1.5 |
구연산 | 0.2 | 0.2 | 0.2 | 0.6 | 0.6 |
하이드록시프로필전분 | 2 | 2 | 2 | 3 | 2 |
스판20 | 0.1 | 0.5 | 0.1 | 0.4 | 0.4 |
멘톨 | 0.4 | 2.3 | 0.3 | 3 | 3 |
카라기난 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 |
색소 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
폴리솔르베이트80 | 0.4 | 0.5 | 0.3 | 0.3 | 0.3 |
페퍼민트오일 | 0.8 | 2.7 | 0.6 | 3 | 3 |
풀루란 | 78.3 | 74.1 | 87.4 | 63.5 | 71.9 |
미세결정셀룰로스 | 1.4 | 1.4 | 0.7 | 0.5 | 3 |
레몬향 | 2 | 2 | 1.5 | 1.5 | 1.5 |
갈란타민 하이드로브로마이드 | 10 | ||||
독사조신 메실레이트 | 10 | ||||
톨테로딘 타르타레이트 | 2 | ||||
파록세틴 하이드로클로라이드 | 20 | ||||
뱀부테롤 하이드로클로라이드 | 10 | ||||
계 | 100 | 100 | 100 | 100 | 100 |
성분 | 실시예 28 (중량%) | 실시예 29 (중량%) | 실시예 30 (중량%) | 실시예 31 (중량%) | 실시예 32 (중량%) |
슈크랄로스 | 1.7 | 1.5 | 2 | 1.5 | |
아스파탐 | 1.5 | ||||
아세설팜칼륨 | 0.5 | 0.6 | 0.7 | 0.5 | |
레바텐 97% | 2 | 2 | 2 | 2 | 1.5 |
구연산 | 0.2 | 0.2 | 0.2 | 0.6 | 0.6 |
하이드록시프로필전분 | 2 | 2 | 3.8 | 3 | 4 |
스판20 | 0.1 | 0.5 | 0.1 | 0.4 | 0.4 |
멘톨 | 0.4 | 2.3 | 0.3 | 3 | 3 |
카라기난 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 |
색소 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
폴리솔르베이트80 | 0.4 | 0.5 | 0.3 | 0.3 | 0.3 |
페퍼민트오일 | 0.8 | 2.7 | 1.6 | 3 | 3 |
풀루란 | 78.3 | 74.1 | 86.4 | 71.5 | 74.9 |
미세결정셀룰로스 | 1 | 1 | 0.4 | 0.5 | 3.5 |
베타사이클로덱스트린 | 0.4 | 0.4 | 0.3 | 0.5 | 0.5 |
레몬향 | 2 | 2 | 1.5 | 1 | 1.5 |
폴코딘 | 10 | ||||
부틸스코폴아민 | 10 | ||||
펜타닐 시트레이트 | 0.2 | ||||
염산 부프레놀핀 | 12 | ||||
염산 옥시코돈 | 5 | ||||
계 | 100 | 100 | 100 | 100 | 100 |
성분 | 실시예 33 (중량%) | 실시예 34 (중량%) | 실시예 35 (중량%) | 실시예 36 (중량%) | 실시예 37 (중량%) |
슈크랄로스 | 1.7 | 1.6 | 2 | 1.5 | |
아스파탐 | 1.5 | ||||
아세설팜칼륨 | 0.5 | 0.5 | 0.7 | 0.5 | |
레바텐 97% | 2 | 2 | 2 | 2 | 1.5 |
구연산 | 0.2 | 0.2 | 0.2 | 0.6 | 0.6 |
하이드록시프로필전분 | 4 | 2 | 3.8 | 3 | 4 |
스판20 | 0.1 | 0.5 | 0.1 | 0.4 | 0.4 |
멘톨 | 0.4 | 2.3 | 0.3 | 3 | 3 |
카라기난 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 |
색소 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
폴리솔르베이트80 | 0.4 | 0.5 | 0.3 | 0.3 | 0.3 |
페퍼민트오일 | 0.8 | 2.7 | 0.6 | 3 | 3 |
풀루란 | 79.3 | 74.1 | 81.6 | 71.5 | 61.9 |
미세결정셀룰로스 | 4.4 | 1.4 | 3.7 | 2.5 | 2 |
레몬향 | 2 | 2 | 1.5 | 1.5 | 1.5 |
염산히드로몰폰 | 4 | ||||
에시탈로프램 옥살레이트 | 10 | ||||
리바스티그민 타르타레이트 | 3 | ||||
아리피프라졸 | 10 | ||||
에소메프라졸 마그네슘 | 20 | ||||
계 | 100 | 100 | 100 | 100 | 100 |
성분 | 실시예 38 (중량%) | 실시예 39 (중량%) | 실시예 40 (중량%) | 실시예 41 (중량%) | 실시예 42 (중량%) |
슈크랄로스 | 1.7 | 1.6 | 1 | 1.5 | |
네오탐 | 1 | 1.5 | |||
아세설팜칼륨 | 0.5 | 0.5 | 0.7 | 0.5 | |
레바텐 97% | 2 | 2 | 2 | 2 | 1.5 |
구연산 | 0.2 | 0.2 | 0.2 | 0.6 | 0.6 |
하이드록시프로필전분 | 3 | 2 | 2.8 | 3 | 4 |
스판20 | 0.1 | 0.5 | 0.1 | 0.4 | 0.4 |
멘톨 | 0.4 | 2.3 | 0.3 | 3 | 3 |
카라기난 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 |
색소 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
폴리솔르베이트80 | 0.4 | 0.5 | 0.3 | 0.3 | 0.3 |
페퍼민트오일 | 0.8 | 2.7 | 0.6 | 3 | 3 |
풀루란 | 79.3 | 74.1 | 68.6 | 79.5 | 79.4 |
미세결정셀룰로스 | 6.9 | 1.4 | 0.7 | 3.5 | 2 |
레몬향 | 2 | 2 | 1.5 | 1.5 | 1.5 |
졸미트립탄 | 2.5 | ||||
리자트립탄 벤조에이트 | 10 | ||||
텔미사르탄 | 20 | ||||
리스페리돈 | 1 | ||||
염산 바데나필 | 2.5 | ||||
계 | 100 | 100 | 100 | 100 | 100 |
성분 | 실시예 43(중량%) | 실시예 44(중량%) | 실시예 45(중량%) | 실시예 46(중량%) | 실시예 47(중량%) | 실시예 48(중량%) |
슈크랄로스 | 1.7 | 1.6 | 1 | 1.5 | 1 | 1 |
네오탐 | 0.5 | 0.5 | ||||
아세설팜칼륨 | 0.5 | 0.5 | 0.7 | 0.5 | ||
레바텐 97% | 2 | 2 | 2 | 2 | 1.5 | 1.5 |
구연산 | 0.2 | 0.2 | 0.2 | 0.6 | 0.6 | 0.6 |
하이드록시프로필전분 | 5 | 2 | 5 | 3 | 4 | 4 |
스판20 | 0.1 | 0.5 | 0.1 | 0.4 | 0.4 | 0.4 |
멘톨 | 0.4 | 1.3 | 0.3 | 3 | 3 | 3 |
카라기난 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 |
색소 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
폴리솔르베이트80 | 0.4 | 0.5 | 0.3 | 0.3 | 0.3 | 0.3 |
페퍼민트오일 | 0.8 | 2.7 | 0.6 | 3 | 3 | 3 |
풀루란 | 79.3 | 75.1 | 78.6 | 79.5 | 79.4 | 72 |
미세결정셀룰로스 | 4.4 | 1.4 | 4.5 | 2 | 2 | 2 |
레몬향 | 2 | 2 | 1.5 | 1.5 | 1.5 | 1.5 |
벤조카인 | 3 | |||||
로라티딘 | 10 | |||||
염산 페닐에프린 | 5 | |||||
염산 디펜히드라민 | 2.5 | |||||
덱스트로메토판 하이드로브로마이드 | 2.5 | |||||
염산 세트리진 | 10 | |||||
계 | 100 | 100 | 100 | 100 | 100 | 100 |
Claims (19)
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201270069A EA021695B1 (ru) | 2009-06-25 | 2010-06-22 | Быстрорастворимая оральная пленочная лекарственная форма, содержащая ребаудиозид а в качестве усилителя послевкусия и первичный подсластитель в качестве агента, маскирующего вкус |
SG2011062379A SG176545A1 (en) | 2009-06-25 | 2010-06-22 | Fast-dissolving oral film for effectively concealing unpleasant tastes |
AU2010263494A AU2010263494A1 (en) | 2009-06-25 | 2010-06-22 | Fast-dissolving oral film for effectively concealing unpleasant tastes |
CA2752865A CA2752865C (en) | 2009-06-25 | 2010-06-22 | Quickly soluble oral film dosage containing steviosides as a unpleasant taste masking agent |
MA34545A MA33439B1 (fr) | 2009-06-25 | 2010-06-22 | Film oral à dissolution rapide pour masquer efficacement les goûts désagréables |
BRPI1007804A BRPI1007804A2 (pt) | 2009-06-25 | 2010-06-22 | dosagem do filme de dissolução rápida por via oral, contendo esteviosídeos como um agente mascarador do sabor desagradável |
US13/260,959 US20120156229A1 (en) | 2009-06-25 | 2010-06-22 | Quickly soluble oral film dosage containing steviosides as a unpleasant taste masking agent |
JP2012513882A JP5539503B2 (ja) | 2009-06-25 | 2010-06-22 | 不快味を効果的に隠蔽した経口用速溶フィルム |
CN201080009753.9A CN102333526B (zh) | 2009-06-25 | 2010-06-22 | 包含作为令人不愉快味道的掩蔽剂的甜菊苷的快速溶解口服膜剂 |
EP10792302.1A EP2431028B1 (en) | 2009-06-25 | 2010-06-22 | Fast-dissolving oral film for effectively concealing unpleasant tastes |
MX2011008698A MX2011008698A (es) | 2009-06-25 | 2010-06-22 | Dosificacion en pelicula oral rapidamente soluble que contiene esteviosidos como agente enmascarador de sabor desagradable. |
ZA2011/06319A ZA201106319B (en) | 2009-06-25 | 2011-08-29 | Quickly soluble oral film dosage containing steviosides as a unpleasant taste masking agent |
US13/572,336 US9492379B2 (en) | 2009-06-25 | 2012-08-10 | Quickly soluble oral film dosage containing steviosides as a unpleasant taste masking agent |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2009-0057276 | 2009-06-25 | ||
KR20090057276 | 2009-06-25 | ||
KR10-2010-0057450 | 2010-06-17 | ||
KR1020100057450A KR101074271B1 (ko) | 2009-06-25 | 2010-06-17 | 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/260,959 A-371-Of-International US20120156229A1 (en) | 2009-06-25 | 2010-06-22 | Quickly soluble oral film dosage containing steviosides as a unpleasant taste masking agent |
US13/572,336 Continuation US9492379B2 (en) | 2009-06-25 | 2012-08-10 | Quickly soluble oral film dosage containing steviosides as a unpleasant taste masking agent |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010151020A2 true WO2010151020A2 (ko) | 2010-12-29 |
WO2010151020A3 WO2010151020A3 (ko) | 2011-05-19 |
Family
ID=43387021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/004020 WO2010151020A2 (ko) | 2009-06-25 | 2010-06-22 | 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 |
Country Status (16)
Country | Link |
---|---|
US (2) | US20120156229A1 (ko) |
EP (1) | EP2431028B1 (ko) |
JP (1) | JP5539503B2 (ko) |
KR (1) | KR101074271B1 (ko) |
CN (1) | CN102333526B (ko) |
AU (1) | AU2010263494A1 (ko) |
BR (1) | BRPI1007804A2 (ko) |
CA (1) | CA2752865C (ko) |
CO (1) | CO6470871A2 (ko) |
CR (1) | CR20110671A (ko) |
EA (1) | EA021695B1 (ko) |
MA (1) | MA33439B1 (ko) |
MX (1) | MX2011008698A (ko) |
SG (1) | SG176545A1 (ko) |
WO (1) | WO2010151020A2 (ko) |
ZA (1) | ZA201106319B (ko) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013527164A (ja) * | 2010-04-26 | 2013-06-27 | インテルジェネクス コーポレイション | タダラフィルを含む固体経口剤形 |
CN103402504A (zh) * | 2011-02-11 | 2013-11-20 | 西梯茜生命工学股份有限公司 | 包含西地那非游离碱的膜制剂及其生产方法 |
CN103417490A (zh) * | 2012-05-21 | 2013-12-04 | 成都康弘药业集团股份有限公司 | 一种含有盐酸多奈哌齐的颗粒剂及其制备方法 |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US10959958B2 (en) | 2014-10-20 | 2021-03-30 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
US11179331B1 (en) | 2020-04-21 | 2021-11-23 | Cure Pharmaceutcai Holding Corp | Oral soluble film containing sildenafil citrate |
CN114366727A (zh) * | 2021-12-22 | 2022-04-19 | 福建瑞泰来医药科技有限公司 | 苹果酸的应用、氢溴酸伏硫西汀口腔速溶膜剂及制备方法 |
WO2023173104A1 (en) * | 2022-03-10 | 2023-09-14 | Thorne Healthtech, Inc. | Phospholipid-containing discs and methods of manufacture |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR045076A1 (es) * | 2003-07-24 | 2005-10-12 | Smithkline Beecham Plc | Composicion de pelicula que se disuelve oralmente, pelicula multicomponente que se disuelve oralmente, uso de la composicion de pelicula y de la pelicula que se disuelve oralmente para preparar un medicamento, forma de dosificacion oral y procedimiento para preparar la composicion de pelicula que se |
JP2012031164A (ja) * | 2010-07-06 | 2012-02-16 | Teika Seiyaku Kk | フィルム状製剤 |
CN103347494A (zh) * | 2010-10-08 | 2013-10-09 | R·P·舍勒科技有限责任公司 | 使用淀粉的口服疫苗快速溶解剂型 |
KR101077468B1 (ko) * | 2011-03-04 | 2011-11-07 | (주)차바이오앤디오스텍 | 안정한 경구용 속용 필름 제제 |
KR101303479B1 (ko) * | 2011-07-28 | 2013-09-06 | (주)씨엘팜 | 가식성 필름형성 조성물 및 약물이 함유된 가식성 필름형 제제 |
KR20130058160A (ko) * | 2011-11-25 | 2013-06-04 | 한국유나이티드제약 주식회사 | 쓴맛이 차폐된 실데나필 시트레이트의 저작정 및 이의 제조방법 |
KR101188594B1 (ko) * | 2011-12-06 | 2012-10-08 | (주)씨엘팜 | 쓴맛이 차단된 실데나필 시트르산의 구강내 속붕해 필름제형 |
JP6200432B2 (ja) * | 2011-12-26 | 2017-09-20 | エスケー ケミカルズ カンパニー リミテッド | モンテルカストまたはその薬学的に許容可能な塩を含む経口投与用フィルム |
KR101383430B1 (ko) * | 2012-01-26 | 2014-04-08 | 광동제약 주식회사 | 새로운 조합의 구강내 속붕해 필름형성 조성물 및 pde5 저해제가 함유된 구강내 속붕해 필름제제 |
JP5941558B2 (ja) | 2012-02-28 | 2016-06-29 | 株式会社ソウル製薬Seoul Pharma. Co., Ltd. | シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム |
CN102600112A (zh) * | 2012-03-13 | 2012-07-25 | 北京阜康仁生物制药科技有限公司 | 一种以芬太尼为主药活性成分的口腔内分散溶解的膜剂 |
AR091349A1 (es) * | 2012-04-30 | 2015-01-28 | Otsuka Pharma Co Ltd | Formulacion oral |
MX362838B (es) | 2012-07-12 | 2019-02-19 | SpecGx LLC | Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente. |
KR101571670B1 (ko) | 2012-08-08 | 2015-11-25 | 주식회사 씨엠지제약 | 아리피프라졸을 포함하는 경구용 속용 필름 제제 |
CN102860997A (zh) * | 2012-09-28 | 2013-01-09 | 天津市聚星康华医药科技有限公司 | 一种遮味的昂丹司琼口腔速溶膜及其制备方法 |
KR101643572B1 (ko) * | 2013-03-07 | 2016-07-29 | 에스케이케미칼주식회사 | 고함량의 약물을 함유하는 구강 붕해 필름 및 이의 제조방법 |
WO2014163215A1 (ko) * | 2013-04-02 | 2014-10-09 | 제일약품주식회사 | 쓴 맛이 차폐된 약제학적 조성물 |
US20160074396A1 (en) * | 2013-04-11 | 2016-03-17 | Ctc Bio, Inc. | Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer |
WO2014182138A1 (ko) * | 2013-05-10 | 2014-11-13 | 주식회사 씨티씨바이오 | 도네페질 유리염기 함유 필름 제제 및 이의 제조 방법 |
KR101553207B1 (ko) * | 2013-08-02 | 2015-09-17 | 주식회사 서울제약 | 도네페질 또는 그의 약제학적으로 허용되는 염을 함유한 구강붕해필름 제제 및 그의 제조방법 |
KR101516875B1 (ko) * | 2013-08-21 | 2015-04-30 | (주)우신메딕스 | 분산성이 개선된 실데나필 시트레이트 구강 붕해 필름 제형 및 이의 제조방법 |
CN105722555A (zh) * | 2013-09-27 | 2016-06-29 | 罗门哈斯公司 | 口部护理组合物 |
WO2015056851A1 (ko) * | 2013-10-18 | 2015-04-23 | 주식회사 한독 | 아리피프라졸 함유 구강 붕해 정제 및 이의 제조 방법 |
CA2931862C (en) | 2013-11-08 | 2024-01-23 | Carlos Filipe | Method of stabilizing molecules without refrigeration using water soluble polymers and applications thereof in performing chemical reactions |
KR101555908B1 (ko) | 2013-12-19 | 2015-09-25 | 한미약품 주식회사 | 몬테루카스트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 액상 제제 및 이의 제조방법 |
CN103750323A (zh) * | 2014-01-26 | 2014-04-30 | 宁夏医科大学 | 一种叶黄素口腔速溶膜及其制备方法 |
KR101478485B1 (ko) * | 2014-03-07 | 2014-12-31 | 조남훈 | 항산화 물질 활성 보호를 위한 프롤라민 기반 경구용 필름 제조방법 |
KR101489752B1 (ko) * | 2014-04-28 | 2015-02-04 | 최명 | 도세탁셀 약물을 함유하는 구강 용해 필름형 항암제 |
CN104083343A (zh) * | 2014-05-08 | 2014-10-08 | 万特制药(海南)有限公司 | 一种草酸艾司西酞普兰口腔速溶膜及其制备方法 |
JP6272730B2 (ja) * | 2014-05-21 | 2018-01-31 | 救急薬品工業株式会社 | 速溶性フィルム剤 |
NZ727834A (en) | 2014-06-24 | 2020-08-28 | Taho Pharmaceuticals Ltd | Fast acting orally disintegrating film |
KR101538985B1 (ko) * | 2014-09-02 | 2015-07-24 | 주식회사 서울제약 | 타다라필 구강붕해필름 및 이의 제조방법 |
CN104224756A (zh) * | 2014-09-26 | 2014-12-24 | 天津市聚星康华医药科技有限公司 | 一种甲磺酸多沙唑嗪口腔速溶膜及其制备方法 |
CN104257637A (zh) * | 2014-09-26 | 2015-01-07 | 天津市聚星康华医药科技有限公司 | 一种酮洛芬口腔速溶膜及其制备方法 |
KR101537263B1 (ko) * | 2014-09-29 | 2015-07-17 | 주식회사 서울제약 | 쓴맛이 차폐된 온단세트론 구강붕해필름 |
CN104586819A (zh) * | 2015-01-05 | 2015-05-06 | 万特制药(海南)有限公司 | 一种治疗老年痴呆病症的药物组合物及制备方法 |
CN104546806A (zh) * | 2015-01-05 | 2015-04-29 | 万特制药(海南)有限公司 | 一种含有利培酮的口腔速溶膜及其制备方法 |
CN104586820B (zh) * | 2015-01-13 | 2021-04-09 | 齐鲁制药有限公司 | 具有高载药量的西地那非口腔速溶薄膜组合物 |
KR20160139704A (ko) * | 2015-05-28 | 2016-12-07 | 주식회사 씨엠지제약 | 아리피프라졸을 포함하는 경구용 속용 필름 제제, 및 이의 제조방법 |
TWI612978B (zh) * | 2015-08-26 | 2018-02-01 | 口溶膜 | |
CN105193769B (zh) * | 2015-09-06 | 2019-02-05 | 合肥华方医药科技有限公司 | 一种盐酸苯海拉明口腔速溶膜剂的制备方法 |
CN106606779A (zh) * | 2015-10-19 | 2017-05-03 | 浙江安吉山争医药包装科技有限公司 | 一种可食性膜片及其制备方法 |
US20180250240A1 (en) * | 2016-03-11 | 2018-09-06 | Intelgenx Corp. | Method of treatment and device for the improved bioavailability of leukotriene receptor antagonists |
US9949934B1 (en) * | 2016-10-20 | 2018-04-24 | Intelgenx Corp. | Device and method of treating conditions associated with neuroinflammation |
RU2617238C1 (ru) * | 2016-03-30 | 2017-04-24 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) | Способ получения лекарственного средства с кислотой янтарной и цетилпиридиний хлоридом местного действия |
WO2017175855A1 (en) * | 2016-04-08 | 2017-10-12 | Shionogi & Co., Ltd. | Stabilized solid dosage form |
CN106389392A (zh) * | 2016-10-13 | 2017-02-15 | 常州市第四制药厂有限公司 | 一种他达拉非口腔溶膜剂及制备方法 |
CN106755194A (zh) * | 2016-12-12 | 2017-05-31 | 青州荣美尔生物科技股份有限公司 | 一种超低粘度瓜尔胶的制备工艺 |
CN108403668B (zh) * | 2017-02-10 | 2021-03-02 | 常州市第四制药厂有限公司 | 缬沙坦口腔崩解膜及其制备方法 |
JP7062368B2 (ja) * | 2017-03-15 | 2022-05-06 | 武田テバファーマ株式会社 | 不快な味がマスキングされた経口医薬組成物 |
BR112019018388A2 (pt) * | 2017-03-30 | 2020-04-07 | Intelgenx Corp | método de tratamento e dispositivo para aumentar a disponibilidade biológica de antagonistas de receptor de leucotrieno |
JP6457582B2 (ja) * | 2017-04-14 | 2019-01-23 | エルメッド エーザイ株式会社 | ガランタミン含有医薬組成物、並びに医薬組成物におけるガランタミンの苦味抑制方法、及びガランタミンの苦味抑制剤 |
CN108926529A (zh) * | 2017-05-25 | 2018-12-04 | 万特制药(海南)有限公司 | 盐酸帕罗西汀口服混悬液及其制备工艺 |
GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
US20200138705A1 (en) * | 2017-06-20 | 2020-05-07 | Seattle Gummy Company | Pectin gummy compostion and methods of making and using thereof |
CN111683671A (zh) | 2017-10-06 | 2020-09-18 | 嘉吉公司 | 制备马黛茶提取物组合物的方法 |
JP2019108284A (ja) * | 2017-12-18 | 2019-07-04 | エスエス製薬株式会社 | 経口用シート状製剤 |
BR112020012239A2 (pt) * | 2017-12-20 | 2020-11-24 | Klaria Pharma Holding Ab | método para preparar um filme mucoadesivo, e, filme mucoadesivo |
KR20190107481A (ko) * | 2018-03-12 | 2019-09-20 | 충북대학교 산학협력단 | 멜록시캄을 포함하는 구강붕해필름 제조방법 및 이에 의해 제조된 멜록시캄을 포함하는 구강붕해필름 |
US11911492B2 (en) | 2018-05-14 | 2024-02-27 | The Procter & Gamble Company | Oral care compositions comprising metal ions |
EP3793507A1 (en) | 2018-05-14 | 2021-03-24 | The Procter & Gamble Company | Oral care compositions comprising fluoride ions |
GB201808462D0 (en) | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
RU2682623C1 (ru) * | 2018-06-21 | 2019-03-19 | Алена Евгеньевна Кормишина | Композиционный энтеросорбент многоцелевого использования |
GB2575625A (en) | 2018-06-22 | 2020-01-22 | Church & Dwight Co Inc | Oral care compositions comprising benzocaine and mucoadhesive thin films formed therefrom |
CN108743567A (zh) * | 2018-08-24 | 2018-11-06 | 北京太阳升高科医药研究股份有限公司 | 氢溴酸加兰他敏口溶膜剂及其制备方法 |
CN109010323A (zh) * | 2018-08-27 | 2018-12-18 | 北京普瑞博思投资有限公司 | 重酒石酸卡巴拉汀口溶膜剂及其制备方法 |
CN109010324B (zh) * | 2018-08-30 | 2021-07-02 | 南京康川济医药科技有限公司 | 一种西地那非口溶膜剂及其制备方法 |
JP2021536467A (ja) | 2018-09-06 | 2021-12-27 | インノファーマスクリーン インコーポレイテッド | 喘息またはパーキンソン病の処置のための方法および組成物 |
CN109106696A (zh) * | 2018-09-25 | 2019-01-01 | 北京普瑞博思投资有限公司 | 吡仑帕奈口溶膜剂及其制备方法 |
CN111166730A (zh) * | 2018-11-13 | 2020-05-19 | 杨守忠 | 盐酸金刚烷胺的速释口溶膜及其制备方法和应用 |
KR20200107809A (ko) | 2019-03-08 | 2020-09-16 | 주식회사 씨에스파마 | 자일리톨 및/또는 효소처리 스테비아로 피복된 복합비타민 과립제 |
KR20200109775A (ko) * | 2019-03-14 | 2020-09-23 | 씨제이제일제당 (주) | 당전이 스테비오사이드 및 당전이 리바우디오사이드 a를 포함하는 조성물 |
EP3952667A1 (en) | 2019-04-06 | 2022-02-16 | Cargill, Incorporated | Sensory modifiers |
EP3980962A1 (en) | 2019-06-10 | 2022-04-13 | The Procter & Gamble Company | Method of generating user feedback information to enhance product use results |
KR102110179B1 (ko) * | 2019-07-18 | 2020-05-13 | 주식회사 서울제약 | 타다라필 또는 그의 약제학적으로 허용되는 염 함유 구강붕해필름 |
KR102044515B1 (ko) | 2019-08-20 | 2019-11-14 | 이영환 | 구강점막 부착력이 우수한 서방형 구강붕해용 필름 및 이의 제조방법 |
CN111012762B (zh) * | 2019-11-05 | 2023-03-14 | 浙江工业大学 | 一种氢溴酸加兰他敏口腔速溶膜剂及其制备方法 |
US20230225953A1 (en) * | 2020-07-14 | 2023-07-20 | Firmenich Sa | Reduction of undesirable taste notes in oral care products |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
KR102413426B1 (ko) * | 2020-12-21 | 2022-06-29 | 주식회사 씨엠지제약 | 나라트립탄을 포함하는 구강용해 필름 제형 |
WO2023073922A1 (ja) * | 2021-10-29 | 2023-05-04 | 日本たばこ産業株式会社 | 難消化デキストリンを含有するオーラル製品および当該製品用組成物 |
CN114557981A (zh) * | 2022-03-02 | 2022-05-31 | 山东新时代药业有限公司 | 一种孟鲁司特钠口腔溶膜剂及其制备工艺 |
CN117180233A (zh) * | 2023-10-23 | 2023-12-08 | 力品药业(厦门)股份有限公司 | 一种经口腔黏膜给药的他达拉非膜剂及其制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001070194A1 (en) | 2000-03-23 | 2001-09-27 | Warner-Lambert Company | Fast dissolving orally consumable films containing an ion exchange resin as a taste masking agent |
WO2003070227A1 (de) | 2002-02-21 | 2003-08-28 | Lts Lohmann Therapie-Systeme Ag | Geschmacksmaskierte film- oder oblatenförmige arzneizubereitung |
US20080044454A1 (en) | 2002-04-11 | 2008-02-21 | Monosolrx Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
WO2008040534A2 (en) | 2006-10-02 | 2008-04-10 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Non-mucoadhesive film dosage forms |
KR20090057276A (ko) | 2006-09-29 | 2009-06-04 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | 패킷화된 시스템의 고속 통신을 위한 비용 효율적인 프리앰블 구조 |
KR20100057450A (ko) | 2008-11-21 | 2010-05-31 | 주식회사 드림이엔지 | 자동 개폐 문비 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000001698A (ko) * | 1998-06-12 | 2000-01-15 | 김재철 | 쓴맛의 은폐효과가 우수한 이부프로펜 함유 약제 |
US20030206942A1 (en) * | 1998-09-25 | 2003-11-06 | Neema Kulkarni | Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent |
JP2000273051A (ja) * | 1999-03-19 | 2000-10-03 | Kobayashi Pharmaceut Co Ltd | 苦みがマスキングされた液状製剤 |
US20030161879A1 (en) * | 1999-06-29 | 2003-08-28 | Shinji Ohmori | Tablets quickly disintegrating in mouth |
JP2001258502A (ja) * | 1999-09-07 | 2001-09-25 | Takeda Chem Ind Ltd | 甘味料組成物、甘味付与方法およびその利用 |
US20040247649A1 (en) * | 2002-02-11 | 2004-12-09 | Edizone, Lc | Medicine-containing orally soluble films |
CN100396332C (zh) * | 2002-05-16 | 2008-06-25 | 救急药品工业株式会社 | 速溶性膜剂 |
US20040265375A1 (en) * | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
KR20040100483A (ko) * | 2003-05-23 | 2004-12-02 | 애경산업(주) | 활성성분 함유 구강용 필름 및 그 제조방법 |
KR20050048056A (ko) * | 2003-11-18 | 2005-05-24 | (주)케이비피 | 경구용 소모 필름 조성물 |
EP1708668A1 (en) * | 2004-01-15 | 2006-10-11 | Oral Bioscience Pty. Limited | Oral anaesthetic gel |
JP2005336078A (ja) * | 2004-05-25 | 2005-12-08 | Nippon Paper Chemicals Co Ltd | マスキング剤 |
US20070116839A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith |
US20070116829A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | Pharmaceutical Composition with High-Potency Sweetener |
DE602007011796D1 (de) * | 2006-10-24 | 2011-02-17 | Givaudan Sa | Verzehrprodukte |
CN100463674C (zh) * | 2006-12-22 | 2009-02-25 | 江苏奥赛康药业有限公司 | 一种氯雷他定口腔速溶膜及其制备方法 |
US20080213320A1 (en) * | 2007-03-01 | 2008-09-04 | Jeremy B. Eisenstein | Compositions for treatment of gastro-esophageal reflux disorders |
WO2008149440A1 (ja) * | 2007-06-07 | 2008-12-11 | Sato Pharmaceutical Co., Ltd. | 速溶性及び可撓性を有するフィルム製剤 |
US20090004254A1 (en) * | 2007-06-19 | 2009-01-01 | Todd Maibach | Film comprising active drugs |
JP5101191B2 (ja) * | 2007-06-29 | 2012-12-19 | リンテック株式会社 | フィルム状製剤およびその製造方法 |
WO2009045022A2 (en) * | 2007-10-03 | 2009-04-09 | C.L. Pharm | Edible film |
KR100905027B1 (ko) * | 2007-10-03 | 2009-06-30 | (주)씨엘팜 | 식용 필름 |
CA2710629C (en) * | 2007-12-27 | 2016-06-21 | Mcneil Nutritionals, Llc | Synergistic sweetening compositions |
-
2010
- 2010-06-17 KR KR1020100057450A patent/KR101074271B1/ko active IP Right Review Request
- 2010-06-22 CA CA2752865A patent/CA2752865C/en active Active
- 2010-06-22 US US13/260,959 patent/US20120156229A1/en not_active Abandoned
- 2010-06-22 JP JP2012513882A patent/JP5539503B2/ja active Active
- 2010-06-22 EP EP10792302.1A patent/EP2431028B1/en active Active
- 2010-06-22 CN CN201080009753.9A patent/CN102333526B/zh active Active
- 2010-06-22 AU AU2010263494A patent/AU2010263494A1/en not_active Abandoned
- 2010-06-22 SG SG2011062379A patent/SG176545A1/en unknown
- 2010-06-22 MA MA34545A patent/MA33439B1/fr unknown
- 2010-06-22 WO PCT/KR2010/004020 patent/WO2010151020A2/ko active Application Filing
- 2010-06-22 MX MX2011008698A patent/MX2011008698A/es not_active Application Discontinuation
- 2010-06-22 BR BRPI1007804A patent/BRPI1007804A2/pt not_active IP Right Cessation
- 2010-06-22 EA EA201270069A patent/EA021695B1/ru not_active IP Right Cessation
-
2011
- 2011-08-29 ZA ZA2011/06319A patent/ZA201106319B/en unknown
- 2011-12-07 CO CO11168582A patent/CO6470871A2/es not_active Application Discontinuation
- 2011-12-14 CR CR20110671A patent/CR20110671A/es unknown
-
2012
- 2012-08-10 US US13/572,336 patent/US9492379B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001070194A1 (en) | 2000-03-23 | 2001-09-27 | Warner-Lambert Company | Fast dissolving orally consumable films containing an ion exchange resin as a taste masking agent |
WO2003070227A1 (de) | 2002-02-21 | 2003-08-28 | Lts Lohmann Therapie-Systeme Ag | Geschmacksmaskierte film- oder oblatenförmige arzneizubereitung |
US20080044454A1 (en) | 2002-04-11 | 2008-02-21 | Monosolrx Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
KR20090057276A (ko) | 2006-09-29 | 2009-06-04 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | 패킷화된 시스템의 고속 통신을 위한 비용 효율적인 프리앰블 구조 |
WO2008040534A2 (en) | 2006-10-02 | 2008-04-10 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Non-mucoadhesive film dosage forms |
KR20100057450A (ko) | 2008-11-21 | 2010-05-31 | 주식회사 드림이엔지 | 자동 개폐 문비 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2431028A4 |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013527164A (ja) * | 2010-04-26 | 2013-06-27 | インテルジェネクス コーポレイション | タダラフィルを含む固体経口剤形 |
CN105250242B (zh) * | 2011-02-11 | 2018-09-21 | 西梯茜生命工学股份有限公司 | 包含西地那非游离碱的膜制剂及其生产方法 |
CN103402504B (zh) * | 2011-02-11 | 2015-10-14 | 西梯茜生命工学股份有限公司 | 包含西地那非游离碱的膜制剂及其生产方法 |
CN105250242A (zh) * | 2011-02-11 | 2016-01-20 | 西梯茜生命工学股份有限公司 | 包含西地那非游离碱的膜制剂及其生产方法 |
CN103402504A (zh) * | 2011-02-11 | 2013-11-20 | 西梯茜生命工学股份有限公司 | 包含西地那非游离碱的膜制剂及其生产方法 |
US9907759B2 (en) | 2011-02-11 | 2018-03-06 | Ctc Bio, Inc. | Sildenafil-free base-containing film preparation and method for producing same |
CN103417490A (zh) * | 2012-05-21 | 2013-12-04 | 成都康弘药业集团股份有限公司 | 一种含有盐酸多奈哌齐的颗粒剂及其制备方法 |
US10639281B2 (en) | 2013-08-12 | 2020-05-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10792254B2 (en) | 2013-12-17 | 2020-10-06 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
US10959958B2 (en) | 2014-10-20 | 2021-03-30 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
US11179331B1 (en) | 2020-04-21 | 2021-11-23 | Cure Pharmaceutcai Holding Corp | Oral soluble film containing sildenafil citrate |
CN114366727A (zh) * | 2021-12-22 | 2022-04-19 | 福建瑞泰来医药科技有限公司 | 苹果酸的应用、氢溴酸伏硫西汀口腔速溶膜剂及制备方法 |
WO2023173104A1 (en) * | 2022-03-10 | 2023-09-14 | Thorne Healthtech, Inc. | Phospholipid-containing discs and methods of manufacture |
Also Published As
Publication number | Publication date |
---|---|
US20120156229A1 (en) | 2012-06-21 |
MA33439B1 (fr) | 2012-07-03 |
JP5539503B2 (ja) | 2014-07-02 |
EP2431028A4 (en) | 2014-04-02 |
MX2011008698A (es) | 2011-10-03 |
JP2012528854A (ja) | 2012-11-15 |
AU2010263494A1 (en) | 2011-08-25 |
CR20110671A (es) | 2012-02-13 |
ZA201106319B (en) | 2012-05-30 |
WO2010151020A3 (ko) | 2011-05-19 |
KR101074271B1 (ko) | 2011-10-17 |
US9492379B2 (en) | 2016-11-15 |
SG176545A1 (en) | 2012-01-30 |
EP2431028B1 (en) | 2017-07-12 |
BRPI1007804A2 (pt) | 2016-02-23 |
KR20100138768A (ko) | 2010-12-31 |
EP2431028A2 (en) | 2012-03-21 |
CN102333526B (zh) | 2014-05-28 |
CN102333526A (zh) | 2012-01-25 |
EA201270069A1 (ru) | 2012-08-30 |
CA2752865C (en) | 2013-11-05 |
EA021695B1 (ru) | 2015-08-31 |
CO6470871A2 (es) | 2012-06-29 |
US20130039932A1 (en) | 2013-02-14 |
CA2752865A1 (en) | 2010-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010151020A2 (ko) | 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 | |
WO2010150930A1 (ko) | 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름 | |
US10456357B2 (en) | Orally administrable formulation | |
WO2012121461A1 (ko) | 안정한 경구용 속용 필름 제제 | |
WO2013129889A2 (ko) | 실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름 | |
CA2658585C (en) | Transmucosal delivery devices with enhanced uptake | |
WO2015072684A1 (ko) | 약리학적 활성 성분을 포함하는 다공성 구강붕해필름 및 이의 제조방법 | |
KR101328350B1 (ko) | 실데나필 또는 이의 약제학적으로 허용되는 염을 유효성분으로 함유하는 고미가 은폐된 약제학적 조성물 | |
KR20120100683A (ko) | 안정한 경구용 속용 필름 제제 | |
KR102153894B1 (ko) | 온단세트론 또는 이의 염을 함유하는 구강 붕해형 필름 제제 및 이의 제조방법 | |
KR101440808B1 (ko) | 실데나필 또는 이의 약제학적으로 허용되는 염을 고함량으로 포함하는 속용필름 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080009753.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10792302 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5991/DELNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2752865 Country of ref document: CA Ref document number: MX/A/2011/008698 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2010263494 Country of ref document: AU Date of ref document: 20100622 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13260959 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2010792302 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012513882 Country of ref document: JP Ref document number: 2010792302 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11168582 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2011-000671 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 002131-2011 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011003274 Country of ref document: CL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201270069 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1007804 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1007804 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110905 |